-0.000109301563012252 -0.000437206252049379 -0.000764892337960413 -2.18603126024503E-05 -0.000579298283965431 -0.00229533282325927 -0.0023569789047983 -0.00200021860312595
Thanks for submitting the form.
Stockreport

Why Analysts See Vertex Pharmaceuticals Story Shifting With New Pipeline Momentum and Valuation Debates [Yahoo! Finance]

Vertex Pharmaceuticals Incorporated (VRTX)  More Company Research Source: Yahoo! Finance
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
Vertex Pharmaceuticals has seen its fair value estimate inch up from about $480 to roughly $485 per share as analysts refresh their models around a more constructive long term growth narrative. Underpinning this shift, research teams are nudging up assumptions for revenue growth while modestly raising the discount rate to reflect a slightly higher perceived risk profile as the story broadens beyond cystic fibrosis. Stay tuned to see how you can track these evolving assumptions and keep ahead of the next turn in the Vertex narrative. [Read more]

IMPACT SNAPSHOT EVENT TIME: VRTX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Stockreport

Why Analysts See Vertex Pharmaceuticals Story Shifting With New Pipeline Momentum and Valuation Debates [Yahoo! Finance]

Vertex Pharmaceuticals Incorporated  (VRTX) 
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
Vertex Pharmaceuticals has seen its fair value estimate inch up from about $480 to roughly $485 per share as analysts refresh their models around a more constructive long term growth narrative. Underpinning this shift, research teams are nudging up assumptions for revenue growth while modestly raising the discount rate to reflect a slightly higher perceived risk profile as the story broadens beyond cystic fibrosis. Stay tuned to see how you can track these evolving assumptions and keep ahead of the next turn in the Vertex narrative. [Read more]

IMPACT SNAPSHOT
EVENT TIME:
VRTX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS